类风湿关节炎中糖皮质激素暴露与严重感染风险:边际结构模型的应用
基于瑞典风湿病质量登记2007–2018年9654例新诊断类风湿关节炎患者的前瞻性起始队列,随访3年,采用边际结构模型校正时变混杂,比较不同口服糖皮质激素剂量模式下严重感染(感染住院)发生率。结果显示,与不用糖皮质激素相比,较低剂量和较高剂量、较近期和较远期暴露均与严重感染发生率升高相关,呈剂量依赖性。
要点
- 与不用糖皮质激素相比,较低剂量和较高剂量、较近期和较远期口服糖皮质激素暴露均与严重感染发生率升高相关。
- 边际结构模型预测,与不用糖皮质激素相比,前6个月使用低剂量者每83人增加1例严重感染。
- 边际结构模型预测,与不用糖皮质激素相比,前3个月使用高剂量者每125人增加1例严重感染。
核心结论
- 结果与既往观察性研究大致一致,显示与(近期)口服糖皮质激素使用相关的剂量依赖性感染风险升高。
研究设计与样本
- 前瞻性起始队列,纳入瑞典风湿病质量登记2007–2018年9654例新诊断类风湿关节炎患者,自首次风湿科就诊后随访3年。
- 随访分为90天时段,计算每个时段的平均口服泼尼松日剂量,分为不用、低剂量(≤10 mg/天)和高剂量(>10 mg/天)。
- 采用合并logistic回归的边际结构模型,允许近期和过去暴露具有独立效应,校正时变混杂。
主要发现
- 与较低剂量相比,较高剂量与严重感染发生率升高相关;与过去暴露相比,较近期暴露与严重感染发生率升高相关。
- 边际结构模型预测,与不用糖皮质激素相比,前6个月使用低剂量者每83人增加1例严重感染。
- 边际结构模型预测,与不用糖皮质激素相比,前3个月使用高剂量者每125人增加1例严重感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Observational studies have reported an increased risk of infections associated with glucocorticoids in RA, not supported by evidence from randomized controlled trials. Inappropriately accommodating time-varying exposure and confounding in observational studies might explain the conflicting results. Therefore, we compared the incidence of serious infections between different oral glucocorticoid dose patterns over three years in a prospective inception cohort, adjusting for time-varying confounders in marginal structural models. METHODS: We included 9654 newly diagnosed RA patients from the Swedish Rheumatology Quality Register between 2007-2018 and followed them for three years after the first rheumatology visit. Follow-up was divided into 90-day periods. A mean oral prednisone daily dose was calculated for each period and categorized into 'no use', 'low' (≤10 mg/day) and 'high' (>10 mg/day) doses. The incidence of serious infections (hospitalization for infection) over follow-up periods was modelled by pooled logistic regression allowing separate effects for recent and past exposure. RESULTS: An increased incidence of serious infections was associated with higher compared with lower doses and with more recent compared with past glucocorticoid exposure. Over 3 years of follow-up, the marginal structural models predicted one additional serious infection for every 83 individuals treated with low GC doses for the first 6 months, and for every 125 individuals treated with high GC doses for the first 3 months, compared with no GC use. CONCLUSION: Our results broadly agree with previous observational studies showing a dose dependent increased risk of infection associated with (recent) use of oral glucocorticoids.
引用
- Barbulescu A, Sjölander A, Delcoigne B, et al. Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application. Rheumatology (Oxford). 2023. PMID: 36821426. doi:10.1093/rheumatology/kead083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。